Maze Therapeutics (MAZE) Stock Price, News & Analysis

Company Overview

Maze Therapeutics, Inc. (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas. By integrating large‐scale genetic datasets with functional genomics assays, the company seeks to uncover previously unrecognized pathways that can be modulated by small molecules or biologics. Its target selection strategy is designed to deliver higher confidence in clinical proof‐of‐concept studies, and Maze’s research collaborations with academic and industry partners support the advancement of its most promising candidates through preclinical and early clinical stages.

Headquartered in South San Francisco, California, Maze Therapeutics operates within a vibrant biotech cluster and draws on a network of scientific advisors and strategic collaborators worldwide. The company is led by a management team with extensive experience in genomics, drug development and translational research. By focusing on genetically validated targets and a disciplined go-to-clinic approach, Maze aims to bring transformative therapies to patients in need while creating value for its shareholders.

Key Stats

• Today's Range: $25.85 to $27.71
• 50-Day Range: $23.58 to $32.84
• 52-Week Range: $12.81 to $53.65
• Volume: 335,578 shs
• Average Volume: 448,123 shs
• Market Capitalization: $1.49 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $66.00
• Consensus Rating: Buy

Maze Therapeutics Stock Analysis - MarketRank™

Maze Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 626th out of 898 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Maze Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 8 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Maze Therapeutics has a consensus price target of $66.00, representing about 145.2% upside from its current price of $26.92.

Amount of Analyst Coverage

Maze Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Maze Therapeutics are expected to decrease in the coming year, from ($2.73) to ($3.35) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Maze Therapeutics is -10.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Maze Therapeutics is -10.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Maze Therapeutics has a P/B Ratio of 3.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.54% of the float of Maze Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Maze Therapeutics has a short interest ratio ("days to cover") of 8.48.

Change versus previous month

Short interest in Maze Therapeutics has recently decreased by 0.03%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Maze Therapeutics does not currently pay a dividend.

Dividend Growth

Maze Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 1.22

News Sentiment

Maze Therapeutics has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.91 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Maze Therapeutics this week, compared to 4 articles on an average week.

MarketBeat Follows

Only 1 people have added Maze Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Maze Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,902,714.00 in company stock.

Percentage Held by Insiders

5.30% of the stock of Maze Therapeutics is held by insiders.

Percentage Held by Institutions

Maze Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/12/2026
• Today: 8/01/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MAZE
• Previous Symbol: NASDAQ:MAZE
• CIK: 1842295
• Web: N/A
• Phone: (650) 850-5070
• Fax: N/A
• Employees: 121
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Maze Therapeutics: $66.00
• High Price Target: $110.00
• Low Price Target: $46.00
• Potential Upside/Downside: +145.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$131.12 million
• Net Margins: N/A
• Pretax Margin: -612.71%
• Return on Equity: -36.62%
• Return on Assets: -31.78%

Debt

• Debt-to-Equity Ratio: 0.11
• Current Ratio: 17.88
• Quick Ratio: 17.88

Sales & Book Value

• Annual Sales: $167.50 million
• Price / Sales: 8.90
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.38 per share
• Price / Book: 3.65

Miscellaneous

• Outstanding Shares: 55,350,000
• Free Float: 52,412,000
• Market Cap: $1.49 billion
• Optionable: N/A
• Beta: 2.14